ARS Pharmaceuticals (NASDAQ:SPRY) Earns Outperform Rating from William Blair

ARS Pharmaceuticals (NASDAQ:SPRY)‘s stock had its “outperform” rating reiterated by equities researchers at William Blair in a research report issued to clients and investors on Friday,RTT News reports.

Several other research analysts have also recently weighed in on the company. Leerink Partners boosted their price target on ARS Pharmaceuticals from $26.00 to $27.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Raymond James boosted their price target on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 14th. Finally, Oppenheimer began coverage on ARS Pharmaceuticals in a research note on Monday, February 10th. They issued an “outperform” rating and a $40.00 price target for the company. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, ARS Pharmaceuticals has an average rating of “Buy” and a consensus target price of $28.80.

ARS Pharmaceuticals Trading Down 4.6 %

ARS Pharmaceuticals stock opened at $11.24 on Friday. The business’s fifty day simple moving average is $12.02 and its two-hundred day simple moving average is $13.25. ARS Pharmaceuticals has a 12 month low of $7.50 and a 12 month high of $18.51. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of -22.04 and a beta of 0.99.

Insider Activity at ARS Pharmaceuticals

In other ARS Pharmaceuticals news, insider Sarina Tanimoto sold 100,000 shares of the business’s stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $13.16, for a total transaction of $1,316,000.00. Following the completion of the sale, the insider now owns 1,148,499 shares of the company’s stock, valued at approximately $15,114,246.84. The trade was a 8.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Justin Chakma sold 25,000 shares of the business’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $14.39, for a total value of $359,750.00. Following the sale, the insider now directly owns 136,380 shares of the company’s stock, valued at $1,962,508.20. This represents a 15.49 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 617,102 shares of company stock worth $7,935,840. 40.10% of the stock is owned by insiders.

Hedge Funds Weigh In On ARS Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. KLP Kapitalforvaltning AS bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $73,000. BNP Paribas Financial Markets bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $75,000. Ball & Co Wealth Management Inc. bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $105,000. Compass Capital Corp MA ADV bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $106,000. Finally, Teacher Retirement System of Texas bought a new position in shares of ARS Pharmaceuticals in the fourth quarter worth about $122,000. Institutional investors own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.